Malin Kele is Business Development Manager at BioLamina AB in Stockholm Sweden. She has a PhD in medicine from Karolinska Institutet in Sweden with a focus on stem cells and tissue engineering.
Between 2014-2019 Malin has managed the Swedish iPS core facility and developed novel xenofree and defined methods to produce human iPS cells and tissue models for disease modelling and drug discovery.
BioLamina is a Swedish biotechnology company with a global presence, built on a scientific foundation, with a legacy in matrix biology and cell culture-based research, founded in 2009. Our headquarters is based in Sundbyberg, Stockholm, with production, quality, R&D, logistics, sales and marketing, and business development all under the same roof.
BioLamina offers an extensive portfolio of chemically defined and animal origin-free cell culture reagents for a variety of applications, including a reliable expansion of pluripotent cells and differentiation and maintenance of specialized cell types, such as keratinocytes, intestinal cells. hepatocytes, and various neural cells. BioLamina’s Biolaminins™ are the only original full length, human, recombinant laminin cell culture substrates on the market and the impact of our Biolaminin matrices on cell culture quality has been scientifically demonstrated